Aptose Biosciences (NASDAQ:APTO) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on Aptose Biosciences in a research note on Saturday, December 7th. They set a “hold” rating for the company.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $0.19 on Tuesday. The company has a market capitalization of $11.46 million, a price-to-earnings ratio of -0.06 and a beta of 1.06. The company’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.51. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.68.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.